Lamotrigine

Generic Name
Lamotrigine
Brand Names
Lamictal
Drug Type
Small Molecule
Chemical Formula
C9H7Cl2N5
CAS Number
84057-84-1
Unique Ingredient Identifier
U3H27498KS
Background

Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...

Indication

Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...

Associated Conditions
Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
Associated Therapies
Conversion to monotherapy
Clinical Trials
Related News

Lamotrigine and Oral Contraceptives

Phase 3
Terminated
Conditions
Epilepsy
First Posted Date
2005-12-15
Last Posted Date
2008-04-24
Lead Sponsor
University of Aarhus
Target Recruit Count
10
Registration Number
NCT00266149
Locations
🇩🇰

Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy

Completed
Conditions
Epilepsy
First Posted Date
2005-12-13
Last Posted Date
2017-10-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
333
Registration Number
NCT00264680

A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis

First Posted Date
2005-11-23
Last Posted Date
2010-02-08
Lead Sponsor
University College London Hospitals
Target Recruit Count
120
Registration Number
NCT00257855
Locations
🇬🇧

National Hospital for Neurology and Neurosurgery, London, United Kingdom

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

Not Applicable
Completed
Conditions
Facial Neuropathy
Interventions
Drug: Placebo (for Lamotrigine)
Drug: Lamotrigine
First Posted Date
2005-10-21
Last Posted Date
2018-12-07
Lead Sponsor
Pain and Analgesia Imaging and Neuroscience Group
Target Recruit Count
6
Registration Number
NCT00243152
Locations
🇺🇸

McLean Hospital Neuroimaging Center, 115 Mill Street, Belmont, Massachusetts, United States

Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Levetiracetam
Drug: Lamotrigine
First Posted Date
2005-10-20
Last Posted Date
2012-05-09
Lead Sponsor
Philipps University Marburg Medical Center
Target Recruit Count
409
Registration Number
NCT00242606
Locations
🇩🇪

Philipps University Marburg Medical Center, Department of Neurology, Marburg, Germany

A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium

Phase 3
Completed
Conditions
Bipolar Disorder
Bipolar Depression
First Posted Date
2005-09-23
Last Posted Date
2017-05-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
120
Registration Number
NCT00224510
Locations
🇪🇸

GSK Investigational Site, Valencia, Spain

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

Phase 4
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-09-22
Last Posted Date
2012-06-20
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
28
Registration Number
NCT00223509
Locations
🇺🇸

Univ of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

First Posted Date
2005-09-22
Last Posted Date
2014-12-03
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
98
Registration Number
NCT00221975
Locations
🇺🇸

University Hospitals of Cleveland, Cleveland, Ohio, United States

Second-Line Treatment Choice for Epilepsy

First Posted Date
2005-09-21
Last Posted Date
2006-09-12
Lead Sponsor
Dutch Epilepsy Clinics Foundation
Target Recruit Count
60
Registration Number
NCT00208520
Locations
🇳🇱

Dutch Epilepsy Clinics Foundation, Zwolle, Netherlands

Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania

Phase 2
Completed
Conditions
Mixed Mania Bipolar Disorder
First Posted Date
2005-09-21
Last Posted Date
2010-11-25
Lead Sponsor
Beth Israel Medical Center
Target Recruit Count
36
Registration Number
NCT00206778
Locations
🇺🇸

Beth Israel Medical Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy